Becton, Dickinson and Company and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, announced a ...
Masimo named Becton Dickinson executive Katie Szyman as its top boss, the medical device maker said on Tuesday, months after longtime CEO and founder Joe Kiani was ousted in a bitter proxy battle with ...
In a recent transaction, Shan David, Executive Vice President and Chief ISC Officer at Becton Dickinson & Co (NYSE:BDX), sold ...
Shares of Becton Dickinson & Co. BDX shed 1.02% to $237.92 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.61% to 6,086 ...
Paoletti, a charge nurse at Jefferson Torresdale Hospital, reported the problem internally, through the health system’s Great ...
Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $237.38 which represents a slight increase of $1.08 or 0.46% from the prior close of $236.3. The stock opened at $236.51 and ...
Barclays analyst Matt Miksic lowered the firm’s price target on Becton Dickinson (BDX) to $278 from $312 and keeps an Overweight rating on the ...
The new versions of BD flow cytometer instrument software compatible with Biosero automation software for the BD FACSymphony A1â„¢ Cell Analyzer, BD FACSymphonyâ„¢ A5 SE Cell Anal ...
Becton, Dickinson and Co. (BD) is investing in its U.S. manufacturing network to add capacity for critical medical devices, ...
Shares of Becton Dickinson & Co. BDX advanced 1.60% to $236.30 Thursday, on what proved to be an all-around poor trading ...
Becton Dickinson's (NYSE:BDX) stock is up by 4.3% over the past month. As most would know, long-term fundamentals ...
(This Jan. 21 story has been corrected to fix the share price gain to 57% from 45% in paragraph 6) (Reuters) - Masimo named Becton Dickinson executive Katie Szyman as its top boss, the medical device ...